416 related articles for article (PubMed ID: 9347791)
1. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
2. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
5. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
6. Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of null/T cell phenotype and in cell lines derived from anaplastic large cell lymphoma.
Foss HD; Demel G; Anagnostopoulos I; Araujo I; Hummel M; Stein H
Pathobiology; 1997; 65(2):83-90. PubMed ID: 9253032
[TBL] [Abstract][Full Text] [Related]
7. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.
Saggini A; Gulia A; Argenyi Z; Fink-Puches R; Lissia A; Magaña M; Requena L; Simonitsch I; Cerroni L
Am J Surg Pathol; 2010 Aug; 34(8):1168-75. PubMed ID: 20661014
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of primary mucosal CD30-positive T-cell lymphoproliferative disorders of the head and neck.
Wang W; Cai Y; Sheng W; Lu H; Li X
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jan; 117(1):96-104. PubMed ID: 24332333
[TBL] [Abstract][Full Text] [Related]
10. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
11. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
[TBL] [Abstract][Full Text] [Related]
12. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.
Beylot-Barry M; Lamant L; Vergier B; de Muret A; Fraitag S; Delord B; Dubus P; Vaillant L; Delaunay M; MacGrogan G; Beylot C; de Mascarel A; Delsol G; Merlio JP
Am J Pathol; 1996 Aug; 149(2):483-92. PubMed ID: 8701987
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
14. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
[TBL] [Abstract][Full Text] [Related]
16. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
17. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
[TBL] [Abstract][Full Text] [Related]
19. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
